Carafa Vincenzo, Altucci Lucia, Nebbioso Angela
Dipartimento di Medicina di Precisione, Università degli Studi della Campania Luigi Vanvitelli, Naples, Italy.
Front Pharmacol. 2019 Jan 30;10:38. doi: 10.3389/fphar.2019.00038. eCollection 2019.
Sirtuins (SIRTs), class III histone deacetylases, are differentially expressed in several human cancers, where they display both oncogenic and tumor-suppressive properties depending on cellular context and experimental conditions. SIRTs are involved in many important biological processes and play a critical role in cancer initiation, promotion, and progression. A growing body of evidence indicates the involvement of SIRTs in regulating three important tumor processes: epithelial-to-mesenchymal transition (EMT), invasion, and metastasis. Many SIRTs are responsible for cellular metabolic reprogramming and drug resistance by inactivating cell death pathways and promoting uncontrolled proliferation. In this review, we summarize current knowledge on the role of SIRTs in cancer and discuss their puzzling dual function as tumor suppressors and tumor promoters, important for the future development of novel tailored SIRT-based cancer therapies.
沉默调节蛋白（SIRTs）属于Ⅲ类组蛋白去乙酰化酶，在多种人类癌症中呈现差异表达，根据细胞环境和实验条件，它们兼具致癌和抑癌特性。SIRTs参与许多重要的生物学过程，在癌症的起始、促进和进展中发挥关键作用。越来越多的证据表明，SIRTs参与调节三个重要的肿瘤过程：上皮-间质转化（EMT）、侵袭和转移。许多SIRTs通过使细胞死亡途径失活并促进不受控制的增殖，导致细胞代谢重编程和耐药性。在本综述中，我们总结了目前关于SIRTs在癌症中作用的知识，并讨论了它们作为肿瘤抑制因子和肿瘤促进因子的令人困惑的双重功能，这对于未来基于SIRT的新型定制癌症治疗的发展具有重要意义。
